PMID- 20862654
OWN - NLM
STAT- MEDLINE
DCOM- 20111229
LR  - 20161125
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Linking)
VI  - 29
IP  - 3
DP  - 2011 Sep
TI  - Follicular lymphoma at relapse after rituximab containing regimens: comparison of 
      time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.
PG  - 131-8
LID - 10.1002/hon.968 [doi]
AB  - Radioimmunotherapies with Zevalin(R) (RIT-Z) showed encouraging results in patients 
      with relapsed/refractory follicular lymphoma (FL), leading frequently to 
      failure-free intervals longer than those achieved by the last previous therapy. 
      We compared time-to-event variables obtained before and after RIT-Z in patients 
      with relapsed FL, previously exposed to rituximab. All patients with relapsed 
      non-transformed, non-refractory, non-rituximab-naive FL who have been treated 
      with RIT-Z in two different centres in Europe were included. Staging and response 
      were assessed by contrast-enhanced CT in all patients; PET/CT was performed 
      according to local availability. Event-free survival (EFS) and time to next 
      treatment (TTNT) following the last previous therapy and after RIT-Z were 
      compared. Pre-therapy characteristics were tested in univariate analyses for 
      prediction of outcomes. A description of the patterns of relapse was also 
      provided. Among 70 patients treated, only 16 fulfilled the inclusion criteria. 
      They were treated with a median of 3 prior lines of chemo-immunotherapies, 
      including a median of 2 rituximab-containing regimens; 6 patients had undergone 
      myeloablative chemotherapy with autologous stem cell rescue (ASCT). Overall 
      response rates were 10 (62%) CR/CRu, 3 (19%) PR and 3 (19%) PD; response rates 
      were similar in patients with prior ASCT. After RIT-Z only few patients obtained 
      EFS and TTNT longer than after the last previous therapy. All four patients 
      receiving rituximab maintenance were without progression 12 months after RIT-Z. 
      Relapses occurred in both previously and newly involved sites; a significant 
      association was found between the number of pathologic sites involved prior to 
      RIT-Z and subsequent TTNT. Despite the excellent response rate, the duration of 
      response was shorter than the previous one confirming the known trend of relapses 
      to occur earlier after subsequent treatments. Rituximab maintenance after RIT-Z 
      showed encouraging results in terms of prolonging EFS, warranting further 
      studies.
CI  - Copyright (c) 2010 John Wiley & Sons, Ltd.
FAU - Cicone, Francesco
AU  - Cicone F
AD  - Department of Nuclear Medicine, Sant'Andrea Hospital, University La Sapienza of 
      Rome, Rome, Italy. f.cicone@iol.it
FAU - Russo, Eleonora
AU  - Russo E
FAU - Carpaneto, Andrea
AU  - Carpaneto A
FAU - Prior, John O
AU  - Prior JO
FAU - Delaloye, Angelika Bischof
AU  - Delaloye AB
FAU - Scopinaro, Francesco
AU  - Scopinaro F
FAU - Ketterer, Nicolas
AU  - Ketterer N
LA  - eng
PT  - Journal Article
DEP - 20100922
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Yttrium Radioisotopes)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 4Q52C550XK (ibritumomab tiuxetan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Murine-Derived/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Lymphoma, Follicular/*drug therapy/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Radioimmunotherapy/*methods
MH  - Recurrence
MH  - Retrospective Studies
MH  - Rituximab
MH  - Yttrium Radioisotopes/*therapeutic use
EDAT- 2010/09/24 06:00
MHDA- 2011/12/30 06:00
CRDT- 2010/09/24 06:00
PHST- 2010/05/23 00:00 [received]
PHST- 2010/07/08 00:00 [revised]
PHST- 2010/08/06 00:00 [accepted]
PHST- 2010/09/24 06:00 [entrez]
PHST- 2010/09/24 06:00 [pubmed]
PHST- 2011/12/30 06:00 [medline]
AID - 10.1002/hon.968 [doi]
PST - ppublish
SO  - Hematol Oncol. 2011 Sep;29(3):131-8. doi: 10.1002/hon.968. Epub 2010 Sep 22.